- 专利标题： MICROBIOTA COMPOSITION, AS A MARKER OF RESPONSIVENESS TO ANTI-PD1/PD-L1/PD-L2 ANTIBODIES AND USE OF MICROBIAL MODULATORS FOR IMPROVING THE EFFICACY OF AN ANTI-PD1/PD-L1/PD-L2 AB-BASED TREATMENT
-
申请号： US16472778申请日： 2017-12-22
-
公开(公告)号： US20210346438A1公开(公告)日： 2021-11-11
- 发明人: Laurence ZITVOGEL , Bertrand ROUTY , Emmanuelle LE CHATELIER
- 申请人： INSTITUT GUSTAVE ROUSSY , INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE - INSERM , UNIVERSITE PARIS-SUD , INSTITUT NATIONAL DE LA RECHERCHE AGRONOMIQUE - INRA
- 申请人地址： FR VILLEJUIF; FR Paris; FR Orsay; FR Paris
- 专利权人： INSTITUT GUSTAVE ROUSSY,INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE - INSERM,UNIVERSITE PARIS-SUD,INSTITUT NATIONAL DE LA RECHERCHE AGRONOMIQUE - INRA
- 当前专利权人： INSTITUT GUSTAVE ROUSSY,INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE - INSERM,UNIVERSITE PARIS-SUD,INSTITUT NATIONAL DE LA RECHERCHE AGRONOMIQUE - INRA
- 当前专利权人地址： FR VILLEJUIF; FR Paris; FR Orsay; FR Paris
- 优先权： EP16306779.6 20161222,EP17305206.9 20170224
- 国际申请： PCT/EP2017/084552 WO 20171222
- 主分类号： A61K35/744
- IPC分类号： A61K35/744 ; A61K39/395 ; C12Q1/6886 ; C12Q1/689
摘要：
The invention relates to gut microbiota profiles associated with response or resistance to treatments with ICB, in particular with anti-PD1 or anti PD-L1 or anti-PD-L2 antibodies. In particular, the invention pertains to a theranostic method for identifying good responders, to whom an anti-PD1 or anti PD-L1 or anti-PD-L2 can be administered, while a pre-treatment based on FMT and/or immunogenic probiotics is recommended to bad responders exhibiting a dysbiosis. In particular, the present invention pertains to Akkermansia muciniphila as the main commensal species distinguishing responders from progressors and its use alone or with E. hirae for the treatment of antibiotics or gut repertoire insufficieny-associated dysbiosis.
公开/授权文献
信息查询
IPC分类:
